These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 18365196

  • 1. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
    Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC.
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
    [Abstract] [Full Text] [Related]

  • 3. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies.
    Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OC, Maranhão RC.
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):565-76. PubMed ID: 15726368
    [Abstract] [Full Text] [Related]

  • 4. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy.
    Mendes S, Graziani SR, Vitório TS, Padoveze AF, Hegg R, Bydlowski SP, Maranhão RC.
    Gynecol Oncol; 2009 Feb; 112(2):400-4. PubMed ID: 19062081
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F, Borgonovo K, Barni S.
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma.
    Azevedo CH, Carvalho JP, Valduga CJ, Maranhão RC.
    Gynecol Oncol; 2005 Apr; 97(1):178-82. PubMed ID: 15790455
    [Abstract] [Full Text] [Related]

  • 14. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y, Sadhukha T, Ma L, Panyam J.
    J Control Release; 2009 May 21; 136(1):21-9. PubMed ID: 19331851
    [Abstract] [Full Text] [Related]

  • 15. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U.
    Clin Pharmacol Ther; 2007 May 21; 81(5):659-68. PubMed ID: 17301739
    [Abstract] [Full Text] [Related]

  • 16. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
    Fruscio R, Lissoni AA, Frapolli R, Corso S, Mangioni C, D'Incalci M, Zucchetti M.
    Cancer Chemother Pharmacol; 2006 Sep 21; 58(3):319-25. PubMed ID: 16362296
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.